Detalles de la búsqueda
1.
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Breast Cancer Res Treat
; 197(2): 319-331, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36401732
2.
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Invest New Drugs
; 40(1): 68-80, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34417912
3.
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Invest New Drugs
; 39(3): 803-811, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33462752
4.
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 271-282, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838007
5.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 261-270, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838015
6.
Novel TLE4-NTRK2 fusion in a ganglioglioma identified by array-CGH and confirmed by NGS: Potential for a gene targeted therapy.
Neuropathology
; 2018 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29502353
7.
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
BJU Int
; 114(6b): E25-E31, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24298897
8.
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.
Clin Cancer Res
; 30(6): 1111-1120, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38226958
9.
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
Cancer Chemother Pharmacol
; 91(3): 239-246, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36884068
10.
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Neuro Oncol
; 24(10): 1776-1789, 2022 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35395680
11.
ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.
Mol Cancer Ther
; 17(1): 222-231, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29054983
12.
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Cancer Discov
; 7(4): 400-409, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183697
13.
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.
NPJ Precis Oncol
; 1(1): 5, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29872694
14.
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Eur Urol
; 70(6): 963-970, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27160947
15.
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
J Thorac Oncol
; 10(12): 1670-4, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26565381
16.
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study.
Cancer Manag Res
; 7: 165-73, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26109878
17.
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Clin Genitourin Cancer
; 12(5): 317-24, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24806399
18.
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
J Clin Oncol
; 32(2): 76-82, 2014 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24323035
19.
Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions.
JCO Precis Oncol
; 22018.
Artículo
en Inglés
| MEDLINE | ID: mdl-31763577
20.
Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer.
JCO Precis Oncol
; 2: 1-7, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35135135